Compare EML & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EML | NYXH |
|---|---|---|
| Founded | 1858 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.9M | 165.0M |
| IPO Year | 1995 | 2021 |
| Metric | EML | NYXH |
|---|---|---|
| Price | $26.12 | $1.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 10.8K | ★ 230.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 185.40 | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $248,970,345.00 | N/A |
| Revenue This Year | $19.05 | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | $26.87 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $1.26 |
| 52 Week High | $29.91 | $6.87 |
| Indicator | EML | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 47.90 |
| Support Level | $24.53 | $1.28 |
| Resistance Level | $27.16 | $1.70 |
| Average True Range (ATR) | 0.95 | 0.09 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 52.00 | 19.12 |
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to the industrial market. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It has one reportable segment: Engineered Solutions, which provides engineered solutions mainly for the commercial transportation and logistics markets. This segment offers a diverse product line of custom and standard vehicular and industrial hardware, including turnkey returnable packaging solutions, blow molds, compression latches, draw latches, hinges, camlocksaccess, mirrors, and mirror-cameras, among other products. Geographically, the group derives maximum revenue from the United States.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.